Advertisement
AMGN or BIIB or PFE
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 4 FA rating(s) are green whileBIIB’s FA Score has 2 green FA rating(s), and PFE’s FA Score reflects 1 green FA rating(s).
- AMGN’s FA Score: 4 green, 1 red.
- BIIB’s FA Score: 2 green, 3 red.
- PFE’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 6 TA indicator(s) are bullish while BIIB’s TA Score has 5 bullish TA indicator(s), and PFE’s TA Score reflects 4 bullish TA indicator(s).
- AMGN’s TA Score: 6 bullish, 3 bearish.
- BIIB’s TA Score: 5 bullish, 4 bearish.
- PFE’s TA Score: 4 bullish, 5 bearish.
Price Growth
AMGN (@Pharmaceuticals: Major) experienced а +2.66% price change this week, while BIIB (@Pharmaceuticals: Major) price change was -1.84% , and PFE (@Pharmaceuticals: Major) price fluctuated -0.32% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.95%. For the same industry, the average monthly price growth was +1.76%, and the average quarterly price growth was +4.67%.
Reported Earning Dates
AMGN is expected to report earnings on Aug 04, 2026.
BIIB is expected to report earnings on Jul 29, 2026.
PFE is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.95% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| AMGN | BIIB | PFE | |
| Capitalization | 203B | 29.9B | 140B |
| EBITDA | 16.7B | 2.7B | 17.2B |
| Gain YTD | 16.558 | 14.887 | 3.641 |
| P/E Ratio | 26.17 | 21.74 | 18.73 |
| Revenue | 37.2B | 9.94B | 63.3B |
| Total Cash | 12B | 4.28B | N/A |
| Total Debt | 57.3B | 6.56B | 63.7B |
AMGN | BIIB | PFE | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | 9 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 10 Undervalued | 86 Overvalued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 18 | 100 | 100 | |
SMR RATING 1..100 | 12 | 79 | 77 | |
PRICE GROWTH RATING 1..100 | 21 | 17 | 53 | |
P/E GROWTH RATING 1..100 | 57 | 14 | 46 | |
SEASONALITY SCORE 1..100 | 50 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PFE's Valuation (3) in the Pharmaceuticals Major industry is in the same range as AMGN (10) in the Biotechnology industry, and is significantly better than the same rating for BIIB (86) in the Biotechnology industry. This means that PFE's stock grew similarly to AMGN’s and significantly faster than BIIB’s over the last 12 months.
AMGN's Profit vs Risk Rating (18) in the Biotechnology industry is significantly better than the same rating for PFE (100) in the Pharmaceuticals Major industry, and is significantly better than the same rating for BIIB (100) in the Biotechnology industry. This means that AMGN's stock grew significantly faster than PFE’s and significantly faster than BIIB’s over the last 12 months.
AMGN's SMR Rating (12) in the Biotechnology industry is somewhat better than the same rating for PFE (77) in the Pharmaceuticals Major industry, and is significantly better than the same rating for BIIB (79) in the Biotechnology industry. This means that AMGN's stock grew somewhat faster than PFE’s and significantly faster than BIIB’s over the last 12 months.
BIIB's Price Growth Rating (17) in the Biotechnology industry is in the same range as AMGN (21) in the Biotechnology industry, and is somewhat better than the same rating for PFE (53) in the Pharmaceuticals Major industry. This means that BIIB's stock grew similarly to AMGN’s and somewhat faster than PFE’s over the last 12 months.
BIIB's P/E Growth Rating (14) in the Biotechnology industry is in the same range as PFE (46) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for AMGN (57) in the Biotechnology industry. This means that BIIB's stock grew similarly to PFE’s and somewhat faster than AMGN’s over the last 12 months.
| AMGN | BIIB | PFE | |
|---|---|---|---|
| RSI ODDS (%) | 3 days ago 41% | 3 days ago 74% | 3 days ago 57% |
| Stochastic ODDS (%) | 3 days ago 55% | 3 days ago 67% | 3 days ago 56% |
| Momentum ODDS (%) | 3 days ago 61% | 3 days ago 61% | 3 days ago 47% |
| MACD ODDS (%) | 3 days ago 61% | 3 days ago 69% | 3 days ago 44% |
| TrendWeek ODDS (%) | 3 days ago 61% | 3 days ago 72% | 3 days ago 59% |
| TrendMonth ODDS (%) | 3 days ago 59% | 3 days ago 62% | 3 days ago 47% |
| Advances ODDS (%) | 3 days ago 59% | 3 days ago 57% | 11 days ago 54% |
| Declines ODDS (%) | 7 days ago 51% | 7 days ago 70% | 7 days ago 58% |
| BollingerBands ODDS (%) | 3 days ago 48% | 3 days ago 80% | 3 days ago 57% |
| Aroon ODDS (%) | 3 days ago 54% | 3 days ago 50% | 3 days ago 60% |
Advertisement
AMGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, AMGN has been loosely correlated with BIIB. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if AMGN jumps, then BIIB could also see price increases.
| Ticker / NAME | Correlation To AMGN | 1D Price Change % | ||
|---|---|---|---|---|
| AMGN | 100% | +1.22% | ||
| BIIB - AMGN | 62% Loosely correlated | +0.78% | ||
| PFE - AMGN | 52% Loosely correlated | -0.16% | ||
| GILD - AMGN | 52% Loosely correlated | -1.18% | ||
| MRK - AMGN | 50% Loosely correlated | +0.45% | ||
| ABBV - AMGN | 47% Loosely correlated | +0.95% | ||
More | ||||
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BMY. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | -0.16% | ||
| BMY - PFE | 61% Loosely correlated | +0.94% | ||
| MRK - PFE | 55% Loosely correlated | +0.45% | ||
| AMGN - PFE | 53% Loosely correlated | +1.22% | ||
| NVS - PFE | 51% Loosely correlated | -0.72% | ||
| BIIB - PFE | 51% Loosely correlated | +0.78% | ||
More | ||||